Shockwave Medical
Shockwave Medical [SWAV] created a highly innovative technology focused on solving the problem of heavily calcified arteries, for patients with Peripheral and Coronary Artery Disease (PAD and CAD). The therapy also has promising applications in aortic valve stenosis.
Sector
Medical Devices
Strategy
Capital
Status
Exit
Website
shockwavemedical.com
Related News
Johnson & Johnson to acquire Shockwave Medical
Shockwave Medical announces agreement to acquire Neovasc
Shockwave Appoints Maria Sainz to Board of Directors
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy
Shockwave Completes Enrollment of Coronary Intravascular Lithotripsy Study in Japan
Shockwave Completes Enrollment in Pivotal Study for Coronary Intravascular Lithotripsy
ShockWave Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Shockwave announces collaboration with Abiomed on physician training
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
Shockwave Medical Announces $35 Million in New Financing
Shockwave Medical Appoints Doug Godshall as President and CEO
Shockwave Medical Raises $45 Million in Series C Financing to Further Advance Novel Lithoplasty Treatment for Calcified Arteries
Shockwave Medical Announces Positive Study Results of Novel Lithoplasty System to Treat Peripheral Artery Disease Consistent, Compelling Results Demonstrated in Data Presented at Charing Cross Symposi
Shockwave Medical Announces $40 Million in Funding for Novel Lithoplasty System to Treat Advanced Peripheral, Coronary Vascular and Aortic Valve Disease
Shockwave Medical Announces CE Mark Approval of its Lithoplasty System for the Treatment of Peripheral Artery Disease
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.